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human hypernephroma cells against irradiation-induced alterations
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Summary There is abundant evidence that inhibitors of prostaglandin (PG) biosynthesis might increase the
radioresponse of certain tumour cells. This study investigated specific PG binding sites, eicosanoid production
as well as intracellular cAMP levels in cultured human hypernephroma cells derived from 11 patients upon
nephrectomy. Scatchard analyses of the binding data revealed specific PGE,-, PGE2- as well as PGI2-binding
sites (PGEI: Bmax = 755 ± 206 fmol mg- protein, Kd = 3.7 ± 2.7nM PGE2: Bmax = 494 ± 221 fmol mg- pro-
tein, Kd = 4.2 ± 2.5nM; PGI2: Bmax = 693 ± 164 fmol mg-' protein, Kd = 6.0 ± 4.5nM). Significant (P<0.01)
increase in PG binding sites expressed on human hypernephroma cells (PGEI: Bmax = 1084 ± 303 fmol mg'-
protein, Kd = 2.8 ± 1.3nM; PGE2: Bmax = 663 ± 309 fmol mg- protein, Kd = 2.2 1.SnM; PGI2: Bmax =
1021 ± 391 fmol/protein, Kd = 4.2 ± 3.6nM) and inhibition of PG biosynthesis (TXB2: - 82.5%, PGE2:
- 87.5%. PGD2: -80.6%, PGF,A: -81.3%) were found after acetylsalicylic acid (ASA)-treatment
(0.5 mg 10-6 cells for 24 h). Following irradiation ('Co, 1.0 Gy/min ' over Omin), PG binding sites (PGE,:
Bmax =266 ± 153 fmol mg-' protein, Kd = 5.0 ± 5.OnM; PGE2: Bmax = 148 ± 66 fmol mg'-I protein, Kd = 4.7 +
3.6nM; PGI2: Bmax = 325 ± 194 fmol mg- protein, Kd = 6.8 ± 7.1nM) were significantly (P<0.01) diminished.
However, irradiation had no significant effect on PG bindig sites in ASA-pretreated cells (PGEI:
Bmax =699 ± 240fmolmg- protein, Kd = 3.5 + 1.8nM; iloprost: Bmax = 766 ± 452 fmol mg-' protein, Kd =
3.2 ± 2.2nM). Although there was no significant difference in the basal values for cAMP between control and
ASA-treated group cells, the PG-induced cAMP-production was less pronounced in the control group.
Taken together, the findings suggest that ASA may modify the radioresponse of cultured human hyperneph-
roma cells by preventing the decrease of PG binding sites induced by irradiation.
Prostaglandins (PGs) are considered to play an important
role in the regulation of tumour cell growth and metastases
formation (Honn et al., 1981). In recent years several studies
have shown that inhibitors of PG biosynthesis, including
indomethacin, may improve the therapeutic effect of chemo-
(Powles et al., 1978), immuno- (Chun & Hoffman, 1987)
and/or radiotherapy (Furuta et al., 1988a) regimens of some
tumours. However, whereas indomethacin remarkably in-
creased tumour cell radioresponse, it had only minimal effect
on the radioresponse of normal tissues such as hair follicles,
jejunum or hematopoietic tissue (Furuta et al., 1988a). Fur-
thermore, the response to indomethacin treatment was
dependent on the ability of the tumour to produce PGs,
mainly PGE2 and PGI2 (Furuta et al., 1988b). Apart from the
fact that the mechanisms by which indomethacin potentiates
tumour radioresponse are still unclear to date, it appears that
an increased tumour response might be achieved by lowering
PGs in the tumour. This, however, would imply that PGs are
not radioprotective agents as has been suggested by Hanson
& Ainsworth (1985) or Walden et al. (1987). Milas and
coworkers (1990) have also found that potentiation of the
tumour radioresponse induced by indomethacin is more
significant when it is given after rather than before irradia-
tion. Beside recent reports on the dependence of
indomethacin-augmented radioresponse on immunocompet-
ence of the tumour host (Milas et al., 1990), another
possibility for PG action on tumour cells would be radiosen-
sitisation by PGs. Moreover, one has also to bear in mind
that the PG production may be remarkably different among
various tumours (Malachi et al., 1981; Ziboh et al., 1981).
PGs exert their effects after interaction with specific cell
surface receptors (Virgolini et al., 1992). We have demon-
strated in human thyroid cancer (Virgolini et al., 1988) and
hepatomas (Virgolini et al., 1989) that the number of PG
receptors significantly (P<0.001) correlates with the cellular
differentiation of the tumour. In these studies we found that
high differentiated cancers seems to possess a higher PG
receptor density than do anaplastic or less differentiated
cancers. Furthermore, patients with a higher PG receptor
density might have a better clinical prognosis. We have now
used a similar receptor assay and have characterised the PG
receptor on cultured human hypernephroma cells. These cells
were shown to produce an increased amount of PGs of the
E-series as compared with normal tissue (Cummings &
Robertson, 1977). Furthermore, hypernephroma cells are
relatively radiosensitive to high-dose radiation therapy
(Halperin & Harisindis, 1983; Lang & deKernion, 1981). In a
further step we wondered to what extent the PG system (PG
receptors, cAMP-formation, PG production) would be
influenced by irradiation, and investigated the effects of
acetylsalicylic acid (ASA) on this system.
Materials and methods
Hypernephroma cell culture preparation
Tissue specimens (approximately 1 cm3) were obtained intra-
operatively from 11 patients aged 61 ± 12 years (nine males
and two females) undergoing nephrectomy for renal cell car-
cinomas. Five of the patients had metastatic cancer, four
were free of metastases. All patients had given written and
informed consent to the study. From each patient a cell line
was cultured. Renal cell carcinoma tissue specimen were
made into a cell suspension by an enzymatic procedure as
follows: suspended cells were incubated on a Petri dish in a
humidified atmosphere of 2.5% CO2, 97.5% 02 at 37°C. The
growth medium was changed three times a week. When the
cells were confluent, a cell suspension was prepared by
incubation with trypsin-EDTA-solution (0.05% trypsin,
0.02% EDTA) in phosphate buffered saline (PBS). Cells were
routinely maintained in medium consisting of nutrient mix-
ture F12 (Ham) supplemented with 12.5% fetal bovine
serum, 0.24 mg collagenase, 0.01 mg DNA-se, 100 I.U.
penicillin and 00 gg streptomycin ml-'. The cells were
plated into 6 cm plastic Petri dishes and stored in the
incubator for 4-18 days for attachment and growth. When
the Petri dishes were densely covered with cells, a single-cell
suspension was prepared. One part of the cell suspension was
plated for further propagation, another part was used for
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testing the multiplication of cells with different concentra-
tions of Cytochalasin B (CB) and one part was plated into
plastic tissue-culture chambers (Lab-Tek), fixed after 24-72 h
and checked for content of cytokeratin as an indicator of
malignancy (Diereck et al., 1991). If there were only
cytokeratin-positive cells, the cell culture was used for com-
bined testing in the second passage. Cultures which were
contaminated with cytokeratin-negative cells were further
propagated and checked again when the cells became
confluent. If there were still cytokeratin-negative cells after
the fourth passage, the cell line was excluded from the test.
Cells from each cell line (one from each patient) were
divided into four groups:
(1) Control group;
(2) ASA-treated group: cells were cultured in the
presence of ASA (Bayer, Leverkusen, Germany; con-
centration 0.5 mg-6 cells ml-' medium for 24h);
(3) Control group irradiated: irradiation was performed
with gamma rays from a 'Co unit (Gammatron,
Siemens) with a source-surface distance of 75 cm and
a dose rate of 1.0 Gy min-' over 10 min. Dose
measurements (calibrations) were carried out with a
standard dosimeter (Farmer 0.6 cm, Nucl. Enter-
prise).
(4) ASA-treated group irradiated: the same irradiation
scheme as in group 3.
Cellular viability was assessed by phase-contrast micro-
scopy and Trypan Blue exclusion criteria (Wandl et al.,
1989).
Binding studies
PG receptor binding studies were carried out according to
the methodology described previously (Virgolini et al., 1992).
All assays reported here were performed approximately 2 h
after irradiation. Briefly, the cells (4-6 x 106 cells in each
group) were washed twice in assay buffer containing 50 mM
Tris-HCI (pH 7.5), 5 mM MgCl2, 1 mM CaC12, 0.1 M NaCI
and centrifuged at 500g for Omin at 4°C (Beckman J-6B
Centrifuge, Munchen, Germany). The pellet was suspended
in 4°C assay buffer at a protein concentration of approx-
imately 300 yg membrane protein ml-' (200-420fg ml-') as
determined by the assay kit provided by Bio-Rad Labor-
atories (Coomassie Brilliant Blue G-250, Richmond, CA). In
preliminary experiments the time course of binding as well as
the dependency of binding on temperature was studied.
Based on the results of these experiments all further incuba-
tions were performed at 4°C for 50 min to ensure equili-
brium.
In saturation experiments hypernephroma cells (300jg protein ml-') were incubated either with increasing concen-
trations of 3H-iloprost (a chemically stable PGI2-analog
(Skuballa & Vorbruggen, 1983); specific activity 14.7 Ci
mmol '; radiochemical purity 98.7%; 0.5-I00 nM), 3H-PGE,
(specific activity 42 Ci mmol 1; radiochemical purity 97.5%;
0.5- 100 nM) or 3H-PGE2 (specific activity 143 Ci mmol ';
radiochemical purity 97.5%; 0.5-98 nM), respectively, in
order to determine total binding (TB). In separate incub-
ation series these increasing concentrations of 3H-iloprost,
3H-PGE, or 3H-PGE2 were incubated in the presence of the
same unlabelled agonist to determine nonspecific binding
(NSB). Specific binding (SB) was expressed as the difference
of total and nonspecific binding. In displacement studies cells
(300jig ml-' protein) were incubated with 15 nM of 3H-
PGEI, 3H-PGE2 or 3H-iloprost in the absence (TB) and
presence of increasing concentrations (10-- 10- M) of
unlabelled agonist (NSB).
After incubation for 50 min at 4°C the reaction was diluted
rapidly with 4 ml of 4°C assay buffer and filtered through a
Whatman GF/B filter (Whatman Inc., Clifton, NY) under
reduced pressure (-60 kPa). The filters were then dried,
transferred into scintillation vials (Packard, Downers Grove,
IL) and taken up into 10 ml scintillation fluid (Pico-Flour
TM30, Packard). The radioactivity in the samples was
counted for 5 min in a liquid scintillation counter (LKB
Wallace, 1215 Rackbeta, Finland).
3H-iloprost, 3H-PGE,, 3H-PGE2 and iloprost were obtained
from Amersham International, Buckinghamshire, UK. Un-
labelled PGE, and PGE2 were purchased from The Upjohn
Company, Kalamazoo, MI.
The inter-assay and intra-assay variability amounted to
6.2 ± 2.7% and 3.9 ± 2.3%, respectively.
Measurement ofcAMPformation
Four to 6 x 106 tumour cells in each group were washed
twice in 50 mM Tris-HCI buffer (pH 7.5) and resuspended in
50 mM Tris-HCI buffer (pH 7.5, 4°C) containing theophylline
(BYK, Gulden Konstanz, Germany, 120 mg 1') to block the
phosphodiesterase and ASA (50 mg1`) to prevent endo-
genous PG synthesis.
Cells were incubated in a 37°C shaking water bath for
30 min with either PGE,, PGE2 or iloprost in a concentration
range from I0-M to 10-9M. After 30min the cells were
homogenised by ultrasound (Sonicator, W-220F, Plainview,
NY) and ultraturrax (TP18/10, Janke & Kunkel GmbH,
Staufen, Germany) for 10s. The incubation was stopped by
centrifugation at 5000g for 10min at 4°C. The cAMP con-
centration in the supernatant was determined by RIA accord-
ing to the manufacturer's description (Amersham). Briefly,
the samples were mixed with 251I-cAMP and rabbit anti-
cAMP serum and incubated for 3 h at 4°C. The antibody-
bound cAMP was then extracted with a donkey anti-rabbit
antibody, which was coated onto magnetisable polymer par-
ticles. These were mixed and left to react with the antibodies
for 10 min at 25°C. The antibody-bound fraction was
obtained with a magnetic separator (Amerlex-M Separator,
Amersham) and the activity was determined by a gamma
counter (Riastar, Packard). The intra-assay variability was
3.5 ± 1.3% and the inter-assay 5.6 ± 2.3%.
Radiothinlayer chromatography
The cells (4-6 x 106 in each group) were resuspended in
50 mM Tris-HCI buffer (pH 7.5) and incubated with 0.25 LCi
'4C-arachidonic acid (AA) (New England Nuclear, Boston,
MA; specific activity 54.5 mCi mmol-'; radiochemical purity
96.3%) for 30 min in a shaking water bath (37°C). The
reaction was stopped with 1 M HCI. After centrifugation at
5000g (10 min, 4°C) the supernatant was extracted with
ethylacetate (Merck, Germany), dried under nitrogen, redis-
solved in absolute ethanol and stored at - 20°C for not
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Figure 1 Time course of specific 3H-PG binding to human
hypernephroma cells. Association: 3H-iloprost (*), 3H-PGE, (O)
(each 84 nM) or 3H-PGE2 (A) (45 nM) was incubated in absence
(total binding) and presence (nonspecific binding) of unlabelled
agonist (100 jAM). Specific binding (shown) was defined as the
difference of total and nonspecific binding. Dissociation: at
equilibrium an excess of the same unlabelled agonist was added.
3H-PGs were displacable within 10 min. Each point represents the
mean ± s.d. of four independent experiments with hyperneph-
roma cells from different cell lines.ASA AND IRRADIATION OF HYPERNEPHROMA CELLS 697
longer than 14 days. The samples were then automatically
(Lamag-Linomat, Hiltons-Syringe, Hamilton, Bonaduz, Swit-
zerland) placed onto a silica gel plate (Merck) together with
the standards (PGE2, PGF2,, 12-HETE, TXB2, PGD2, New
England Nuclear). The plate was put into a glass chamber
with the lower edge in organic phase which consisted of
chloroform, acetic acid, H20 and methanol (90:1:0.7:8) until
the organic phase had reached the upper edge. Then the plate
was removed and analysed by an automatic TLC-analyser
(LB283, Berthold, Wilbad, Germany) coupled with an oscil-
loscope (Time ADL, Berthold).
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Analysis
Binding data were analysed according to Scatchard (1949)
using a computer programme which searched systematically
for the highest level of correlation under the model of two
straight lines in the given interval and tested against the
alternative of single straight line approximation. Values are
presented as means (X) ± standard deviations (s.d.).
Statistical analysis was done by standard statistical tests
including Student's t test and ANOVA at a confidence level
of 95%.
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Binding of3H-iloprost, 3H-PGE, and 3H-PGE2 to cultured
human hypernephroma cells
In initial experiments the time course of 3H-iloprost, 3H-
PGE1 and 3H-PGE2-binding to human hypernephroma cells
was investigated showing a constant increase of 3H-ligand
specifically bound during the first min of incubation (Figure
1). Equilibrium was reached within 20 min in 3H-iloprost and
3H-PGE, binding experiments and within 30 min in 3H-PGE2
binding experiments, and remained stable for at least 80 min.
No significant numbers of cells were lost over the time scale
of the experiments.
Specific 3H-iloprost, 3H-PGE, and 3H-PGE2 binding was
only slightly dependent on temperature and was insig-
nificantly lower at 37°C and at 22°C than at 4°C.
3H-iloprost, 3H-PGE1 and 3H-PGE2 binding to human
hypernephroma cells could be displaced by unlabelled ilo-
prost, PGEI and PGE2, respectively. In 3H-iloprost binding
studies the concentrations of unlabelled iloprost, PGE,, PGE2
for causing half maximal inhibition (IC50) were
81± 25 x10-9M, 12±6x 10-8M and 9±3x 10-6 M, res-
pectively. The IC50 values were 40 ± 10 x 10-9 M for PGEI,
86 ± 20 x 10-9 M for iloprost, and 85 ± 26 x 10-6 M for
PGE2 in 3H-PGE, binding experiments, and amounted to
42 ±9 x 10-9M for PGE2, 4±2x 10-6 M for PGE1 and
30± 7 x 10-6 M for iloprost in 3H-PGE2 binding studies
(Figure 2a-c).
Saturation of 3H-PG binding to human hypernephroma
cells was studied by incubating increasing concentrations of
ligand in the absence and presence of an excess of the same
unlabelled agonist. Binding was saturable and indicated a
single class of high affinity binding sites for all three ligands
within the ligand range studied (Figure 3a-b). After prein-
cubation of the cells with ASA (group 2) a significantly
(P<0.01) increased capacity to bind the PGs was found.
The respective binding data are given in Tables I-III show-
ing that ASA treatment increased 3H-iloprost receptors from
693 ± 164 to 1021 ± 391 fmol mg-' protein (P<0.05), 3H-
PGEI-receptors from 755 ± 206 to 1084 ± 303 fmol mg-'
protein (P<0.01) and 3H-PGE2-receptors from 494 ± 221 to
663 ± 309 fmol mg-' protein (P<0.05). Increase in the bin-
ding capacity was accompanied by a significant (P<0.05)
decrease in the dissociation constant Kd.
In order to investigate the effect of irradiation on
hypernephroma cells, irradiation with 'CO at a dose rate of
1 Gy min-' was performed. All binding experiments were
carried out at approximately 2 h after irradiation. At this
time cellular viability was unchanged. Irradiation caused a
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Figure 2 a-c Ability of unlabelled PG to compete with 3H-PG
for binding to human hypernephroma cells. Each assay tube
contained 15 nM 3H-PG (3H-iloprost a; 3H-PGE, b; 3H-PGE2 c)
and the indicated concentrations of corresponding unlabelled
agonist (iloprost (*), PGE, (O) and PGE2 (A)) Each point
represents the mean ± s.d. of three independent experiments from
different cell lines.
significant decrease in 3H-PG-receptors: 3H-iloprost receptor
decreased to 325 ± 194 fmol mg-' protein (P<0.001), 3H-
PGE1-receptors to 266 ± 153 fmol mg-' protein (P<0.001),
and 3H-PGE-receptors to 148 ± 66 fmol mg-' protein (P<
0.01). After pre-treatment with ASA the decrease induced by
irradiation was much less pronounced (P>0.05) (3H-iloprost
receptors: 766 ± 452 fmol mg-' protein, 3H-PGE,-receptors:
699 ± 240 fmol mg-' protein, 3H-PGE2-receptors: 287 ± 114
fmol mg-' protein).
Effect ofPGs on cAMP-formation
There was no significant difference in basal values between
control (30.1 ± 10.5 pmol mg-') and ASA-treated group
(28.0 ± 11.5 pmol mg-' protein). However, the basal values
of control group irradiated (17.6 ± 8.9 pmol mg-' protein)
and of ASA-treated group irradiated (15.8 ± 6.1 pmol mg-'
protein) were significantly (P<0.001) lower as compared to
the control group.
Iloprost, PGE, and PGE2 significantly (P<0.01) stim-
ulated cAMP-production in all four groups dose-depen-
dently. However, the half maximal effective doses (ED50)
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were significantly different between the four groups (Figure Conversion ofexogenously added '4C-AA to its metabolites 4a-c). The corresponding ED_% values for iloprost were
12 ± 8 x Io-' M for the control group, 35 ± i3 x l0-7 M for Hypernephroma cells converted exogeneous precursor AA to
the ASA-treated group, 80 ± 21 x 10-7 M for the control a various number of compounds (HETE, PGD2, thrombox-
group irradiated, and 43 ± 11 x 10-7 M for the ASA-treated ane B2 (TXB2), PGE2, PGF2J) (Table IV). The main
group irradiated. The ED50 for PGE, were 25 ± 8 x 10-5 M metabolites of AA conversion of cultured hypernephroma for the control group, 30 ± 10 x 10-7 M for the ASA-treated cells were PGE2 and TXB2 in both the control and the
group, 11 ± 6 x 10-7 M for the control group irradiated, and irradiated groups. After ASA treatment, PG production was
88 ± 15 x 10-7 M for the ASA-treated group irradiated. The significantly decreased - the main metabolite of AA conver-
corresponding ED50 values for PGE2 were 11 ± 4 x 10-5 M sion was HETE.
for the control group, 61 ± 22 x 10-8 M for the ASA-treated
group, 86 32 x 10-7 M for the control group irradiated, Discussion
and 33 ± 12 x 10-8 M for the ASA-treated group irradiated.
Previously, we have identified and described PG binding sites
a on tumour cells (Virgolini et al., 1988, 1989) and have dem-
onstrated that cellular differentiation could be closely
associated with receptor density and binding affinity. In this
.' 600- study comparable low numbers of specific binding sites for 3H-PGEI, 3H-PGE2 as well as 3H-iloprost were found on
cultured human hypernephroma cells which resemble the
i, 400 , z _results obtained for thyroid cancer (Virgolini et al., 1988) and
E human hepatocellular cancer (Virgolini et al., 1989). We -a Al /(Virgolini et al., 1988, 1989) and others (Robertson et al.,
!tn 200 ing sites in malignant tissues which might be due to an C g increased PG-production by malignant cells (Bennett et al., ffi 1982; Porteder et al., 1984).
0 Elevated PG production was found in various tumour
20 40 60 80 100 tissues (Honn et al., 1981; Bennett et al., 1982; Porteder et 3H-PG (nM) al., 1984). However, the type of PG produced by tumour
0.12 - b cells as well as the capacity of the tumour cells to synthesise PGs are highly variable (Malachi et al., 1981; Ziboh et al., 0.10 \1981). Cummings and Robertson (1977) have provided
4)0.08-, wX evidence for an increased production of PGs by human hypernephroma tumour tissues. They found increased levels '0.06V - of PGA and PGE in cultured hypernephroma cells, in ex- m 0 04 >, \ tracts of primary and metastatic hypernephroma tissues and -0.0V in the venous effluent of a hypernephroma bearing kidney. In
0.02- accordance with their findings we have now demonstrated
that cultured human hypernephroma cells are able to pro-
0 duce various eicosanoids (PGE2, PGF2a, TXB2, PGD2 and
100 200 300 400 500 600 700 12-HETE) with PGE2 being the main metabolisation pro-
Bound duct.
Figure 3 a-b Saturation experiments of 3H-PG binding with For all three PG receptor subtypes investigated we found a human hypernephroma cells. a, Saturation curve of specific 3H- linear Scatchard plot indicating a single class of binding sites PG binding. b, Corresponding Scatchard analysis. Each point within the concentration ligand ranges studied. Comparable
represents the mean of six independent experiments with hyper- numbers of binding sites were found for 3H-iloprost and nephroma cells from different cell lines. (-) 3H-iloprost binding; 3H-PGE1 with a Kd value of about 4 nM for 3H-PGE1 binding (0) 3H-PGE,-binding; 3H-PGE2-binding (A). and of 6 nM 3H-iloprost binding on the average. While for
Table I 3H-iloprost binding to cultured human hypernephroma cells
Without irradiation Irradiation
Control ASA Control ASA
(group 1) (group 2) (group 3) (group 4) Pat. Age Sex TNM Stage Bax Kd Bmax Kd Bm. Kd Bmax Kd
1 45 m T3NoMx II 741 10.0 813 8.7 2 78 m T3NoMx II 635 12.0 855 10.0 - - - - 3 48 f T3NoMx II 876 13.0 987 10.0 332 21.0 489 6.9 4 62 m T3NoMo II 732 10.0 960 4.3 287 5.7 354 4.95 5 46 m TlNoMx II 808 1.0 916 1.0 6 69 m T3NoMx III 806 3.6 1047 2.1 432 10.3 867 4.2 7 56 m T2NoMo II 649 1.8 2024 1.2 699 1.3 1551 1.1 8 69 m T3NoMo I 407 3.2 1301 3.3 9 70 f T2NoMo II 382 3.6 442 1.8 204 1.5 364 1.9 10 48 m T3NlMo II 829 1.3 1023 1.5 203 6.1 1162 1.9 11 74 m T3NlMo III 756 6.3 861 2.1 118 1.7 576 1.3
61 693 6.0 1021a 4.2b 325c 6.8 766d 3.2b ±s.d. ±12 ±164 ±4.5 ±391 ±3.6 ±194 ±452 ±2.2
Bm.: binding capacity in fmol mg-' protein; Kd: (dissociation constant) in nM; not investigated. ap<0.05, bp<0.0 , Cp<0.001, vs the control group (without irradiation). dp<0.05, vs the irradiated control group. Significant (P<0.05) increase in 3H-iloprost receptors expressed on hypernephroma cells was found after pre-treatment with ASA which also led to a significant (P<0.05) increase in the binding affinity. Irradiation caused significant (P<0.001) depression of 3H-iloprost receptors while the binding affinity remained unchanged. IrradiatedASA-pretreated cells had asimilarbindingcapacity to theplanecontrolgroupandasignificantly (P<0.05) higheroneascompared with the irradiated control group.ASA AND IRRADIATION OF HYPERNEPHROMA CELLS 699
most cells 3H-PGE, as well as 3H-iloprost seem to bind to
two binding classes with different affinity (Virgolini et al.,
1992), our results on cultured human hypernephroma cells
indicate a single class of high affinity sites for either ligand.
Furthermore, the competition studies show that 3H-iloprost
could recognise 3H-PGE, sites as does 3H-PGE, with 3H-
iloprost sites vice versa, pointing to a common PGEI/PGE2
binding site on human hypernephroma cells. As with non-
malignant cells (Virgolini et al., 1992) 3H-PGE2 did not bind
to PGE1/PGE2 binding sites suggesting a distinct class of
3H-PGE2 binding sites.
In order to study the effects of ASA on the PG-system of
human hypernephroma cells an incubation was performed
for 24 h. ASA significantly depressed PG-production and
increased PG receptor densities and binding affinities,
whereas cellular viability remained unchanged. These results
indicate that ASA renders human hypernephroma cells
more sensitive for binding PGE,, PGE2 as well as iloprost.
Whether or not there exists a down-regulation mechanism on
the basis of an increased PG production by human
hypernephroma cells is not yet clear.
Recently a number of studies in murine tumours have
shown that indomethacin significantly increases radiores-
ponse of tumours which produce PGs (Furuta et al., 1988a,
1988b). Initially it was proposed that the augmentation of
radioresponse induced by indomethacin could be due to
lowering PGs in tumour tissues. The effects of PGs on
radioprotection are, however, not clear: some authors
reported that PGs might act as radioprotectors (Hanson &
Ainsworth, 1985; Walden et al., 1987), whereas others (Milas
et al., 1990) proposed an opposite effect.
PGs exert their effects through interaction with specific cell
surface receptors. There is little information about PG recep-
tor expressed by tumour cells after radiotherapy. We were
now able to show that although the number of PG binding
sites was significantly diminished after irradiation with 'Co,
no significant change in the number of PG binding sites was
found for human hypernephroma cells after pre-incubation
with ASA. The results indicate that the PG synthesis
inhibitor ASA could protect against an irradiation effect on
PG receptors, modifying the radioresponse of human
hypernephroma cells.
Table II 3H-PGE, binding to cultured human hypernephroma cells
Without irradiation Irradiation
Control ASA Control ASA
(group 1) (group 2) (group 3) (group 4)
Pat. Bmax Kd Bmax Kd Bmax Kd Bmax Kd
1 781 10.0 811 5.0
3 372 5.0 923 2.9 267 7.1 679 5.0
4 978 2.0 1076 3.0 - - - -
5 911 5.0 1019 5.0 - - - -
6 694 4.8 1367 3.0 504 13.2 867 5.0
7 893 1.3 897 1.5 301 3.2 615 2.4
8 1041 2.7 1773 1.7 - - - -
9 643 1.5 736 1.4 137 1.1 268 1.3
10 555 1.8 1064 1.9 319 3.3 884 3.0
11 685 2.9 1171 2.3 68 1.8 879 1.1
x 755 3.7 1084b 2.8a 266c + 50 699d 3.0
±s.d. ±206 ±2.7 303 ±1.3 ±153 - ± 240 ±1.7
Bmax: binding capacity in fmolmg-' protein; Kd: (dissociation constant) innM; -: not investigated.
ap<0.05, bP<0.01, CP<0.001, vs the control group (without irradiation). dP<0.01, vs the
irradiated control group. Significant (P< 0.01) increase in 3H-PGE, receptors expressed on human
hypernephroma cells was found after pre-treatment with ASA which also led to a significant
(P<0.05) increase in the binding affinity. Irradiation caused a significant (P<0.001) depression of
3H-PGE, receptors without change in the binding affinity. Irradiated ASA-pre-treated cells had a
similar binding capacity to the plane control group and a significant (P<0.01) higher one as
compared with the irradiated control group.
Table III 3H-PGE2 binding to cultured human hypernephroma cells
Without irradiation Irradiation
Control ASA Control ASA
(group 1) (group 2) (group 3) (group 4)
Pat. Bmax Kd Bmax Kd Bmax Kd Bmax Kd
1 563 3.0 650 3.5
3 143 5.0 162 1.0 63 4.6 181 2.0
4 478 6.0 858 4.0 - - - -
5 650 2.0 780 2.0 - - - -
6 930 7.7 1104 4.6 209 9.0 336 6.0
8 438 1.0 986 1.2 218 2.2 338 3.0.
9 534 1.1 666 1.0 112 1.2 466 1.2
10 313 5.8 324 0.3 96 2.0 232 3.6
11 398 6.3 441 2.3 189 9.1 170 5.0
x 494 4.2 663a 2.2a 148 + 287c 3.5c
±s.d. ±221 ±2.5 309 ±1.5 ± 66 _3.6 ±114 ±1.8
Bmax: binding capacity in fmol mg 'protein; Kd: (dissociation constant) innM; -: not investigated.
ap<o.05 "p b 0.01, vs the control group (without irradiation). CP<0.05, vs the irradiated control
group. Significant (P< 0.05) increase in 3H-PGE2 receptors expressed on human hypernephroma
cells was found afterpre-treatment with ASA which also led to a significant (P<0.05) increase in the
binding affinity. Irradiation caused a significant (P<0.01) depression of3H-PGE2 receptors without
change in the binding affinity. Irradiated ASA-pretreated cells had a significantly (P<0.05) higher
number of 3H-PGE2 receptors as irradiated ASA-untreated cells, however values were still
significantly (P<0.05) lower than in the control group.700 S.-R. LI et al.
a Table IV Effects ofASA and irradiation on '4C-AA conversion (in %)
T__ by human hypernephroma cells
40
:
= 0) *0 4-
0 0
U)
lloprost (nM)
b
basal 0.001 0.01 0.1 1.0 10 100
PGE1 (nM)
200
C
*
Control group (group 1)
Pat. TXB2 PGE2 PGD2 PGF2,. 12-HETE AA (%)
1 8.5 12.3 2.2 2.3 4.2 65.2
3 6.2 11.0 2.1 2.4 3.8 58.9
4 11.8 20.1 3.1 3.9 4.5 49.3
6 7.3 7.9 3.9 4.2 3.1 68.9
8 5.9 9.8 4.7 2.9 4.8 62.9
9 8.9 15.3 5.1 3.8 3.1 59.8
11 7.7 7.5 3.9 2.9 2.1 67.8
x±s.d. 8.0 12.0 3.6 3.2 3.7 61.8
±2.0 ±4.5 ±3.6 ±0.8 ± 1.0 +6.7
ASA-treated group (group 2)
1 1.2 1.8 1.3 1.7 6.9 66.5
3 0.8 1.1 0.9 0.7 4.2 78.2
4 1.7 2.2 0.2 0.8 7.3 72.9
6 1.3 0.7 0.5 0.2 5.5 78.5
8 1.3 1.5 0.4 0.3 5.3 82.8
9 2.3 1.8 0.6 0.5 4.9 81.0
11 1.5 1.3 0.8 0.3 8.8 78.5
x ± s.d. 1.4ce i.ce 07b,e 0.6ce 6.1a,d 76.9b
±0.5 ±0.5 ±0.4 ±0.5 ±1.6 +5.5
Control group irradiated (group 3)
1 6.6 8.3 2.9 2.1 4.6 70.4
4 8.2 9.3 3.1 3.9 5.2 63.2
6 6.9 7.8 3.3 2.5 4.3 68.9
9 9.1 10.5 2.9 2.6 3.6 65.2
11 6.4 9.3 2.9 2.4 2.8 67.5
x ± s.d. 7.4 9.0 3.0 2.7 4.1 67.0
± 1.2 ± 1.0 ±0.2 ±0.7 ±0.9 +2.9
ASA-treated group irradiated (group 4)
3 1.3 0.8 0.3 0.5 4.9 82.9
4 1.2 1.6 0.9 0.9 5.1 74.3
6 1.1 1.9 0.8 0.2 4.8 81.2
9 1.5 1.1 0.5 0.8 4.8 73.7
11 0.6 1.8 0.4 0.4 5.1 79.4
x+s.d. 1.1c,f 1.4c.f 0.6f 0.6c,f 4.9a 78.3c,e
±0.3 ±0.5 ±0.3 ±0.3 ±0.2 ±4.1
ap<0.05 bp<0.01, cp<0.001, vs the control group (group 1).
dp<O.05, eP<0.01, fp<0.001, vs the irradiated control group.
basal 0.001 0.01 0.1
PGE2 (>M)
Figure 4 a-c Effects of aspirin and irradi
duction of hypernephroma cells stimulated
trations of PGs (iloprost a, PGE, b, PGE2 c
means of four independent experiments.-
-0-: ASA-treated group; --- control grs
ASA-treated group irradiated. *P<0.05, **
value in each group.
The presence of PGs as well as PG ri
human hypernephroma cells suggests .
tumour growth and possibly its metastas
already been reported that certain syndro
hypernephromas such as the osteolytic
secutive hypercalcaemia might result fror
hypernephroma cells (Robertson et al.,
Robertson, 1977). Furthermore, increases
tumours has been associated with a
inhibitors of PG synthesis including ASA
were reported to retard tumour growth
mation (Lynch et al., 1978; Bennett,, 19
cAMP is a second messenger mediating the actions of PGs
and also connected with normal and malignant cell prolifera-
tion. It is likely that changes in intracellular cAMP-
1.0 10 100 production due to PG stimulation may greatly influence
tumour cell growth and even metastases formation (Heidrick
& Ryan, 1971; Sheppard, 1972). However, both reduced
ation on cAMP-pro cAMP levels (Malachi et al., 1981; Goldberg et al., 1975;
by different concen- Stevens et al., 1978) and elevated cAMP contents (Minton et
). Values indicate the al., 1976; Kung et al., 1977) have been reported in tumour
-O-: control group; tissues. This may correlate to the different PG levels found
Dup irradiated; -0-: for various tumour tissues. For cultured human hyperneph-
P< 0.01 vs the basal roma cells we found no significant difference in basal cAMP
levels in both non-ASA-treated and ASA-treated cells. How-
ever, the PG-stimulated cAMP-production was significantly
higher in the ASA-treated group as compared with the con-
trol group. This suggests that down-regulation of PG recep-
eceptors in cultured tors was associated with decreased adenylate cyclase activity
a role for PGs in stimulated by PGs.
,es formation. It has We here show that ASA modifies the radioresponse of
mes of patients with human hypernephroma cells by preventing the irradiation-
process and con- induced decrease of PG receptors, which might cause a
m PGs produced by corresponding decrease in PG-induced membrane adenylate
1975; Cummings & cyclase activity.
I PG production by
Lggression, whereas
k and indomethacin
and metastases for-
182).
The authors are grateful for the expert technical assistance of Ingrid
Teufel and Regina Haslinger.
This study was supported by a grant of the 'Kommission fur
Onkologie', University of Vienna, Vienna, Austria.
-0.: .r- 0
0- O:
-0 4
o00
._) O °0
< _-
0
O
.-ASA AND IRRADIATION OF HYPERNEPHROMA CELLS 701
References
BENNETT, A. (1982). Effect of prostaglandin synthesis inhibitors on
tumor growth in vivo. In Prostaglandins and Cancer: First Interna-
tional Conference, Powles, T.J., Bockman, R.S., Honn, K.V. &
Ramwell, P. (eds) Vol. 2, pp. 759-766. Alan R. Liss Inc.: New
York.
BENNETT, A., CARROLL, M.A., STAMFORD, I.F., WHIMSTER, W.F. &
WILLIAMS, F. (1982). Prostaglandins and human lung car-
cinomas. Br. J. Cancer, 46, 888-893.
CHUN, M. & HOFFMAN, M.K. (1987). Combination immunotherapy
of cancer in a mouse model: synergism between tumor necrosis
factor and other defence systems. Cancer Res., 47, 115-118.
CUMMINGS, K.B. & ROBERTSON, R.P. (1977). Prostaglandin: in-
creased production by renal cell carcinoma. J. Urol., 118,
720-723.
DIERECK, A.M., PRAET, M., ROELS, H., VERBEECK, P., ROBYNS, C.
& OOSTERLINCK, W. (1991). Vimetin expression of renal car-
cinoma in relation to DNA content and histological grading: a
combined light microscopic, immunocytochemical and cyto-
photometrical analysis. Histopathology, 18, 315-322.
FURUTA, Y., HUNTER, N., BARLEY, T. Jr, HALL, E. & MILAS, L.
(1988a). Increase in radioresponse of murine tumors by treatment
with indomethacin. Cancer Res., 48, 3008-3013.
FURUTA, Y., HALL, E.R., SANDUJA, S., BARKLEY, T. Jr & MILAS, L.
(1988b). Prostaglandin production by murine tumors as a predic-
tor for therapeutic response to indomethacin. Cancer Res., 48,
3002-3007.
GOLDBERG, M.L., BURKE, G.C. & MORRIS, H.P. (1975). Cyclic AMP
and cyclic GMP content and binding in malignancy. Biochem.
Biophys. Rev. Comm., 62, 320-327.
HALPERIN, E.C. & HARISINDIS, L. (1983). The role of radiation
therapy in the management of metastatic renal cell carcinoma.
Cancer, 51, 614-617.
HANSON, W.R. & AINSWORTH, E.J. (1985). 16,16-Dimethyl pros-
taglandin E2 induces radioprotection in murine intestinal and
hematopoietic stem cells. Radiat. Res., 103, 196-203.
HEIDRICK, M.L. & RYAN, W.L. (1971). Adenosine 3'5'-cyclic
monophosphate and contact inhibition. Cancer Res., 31,
1313- 1315.
HONN, K.V., BOCKMAN, R.S. & MARNETT, L.J. (1981). Prostaglan-
dins and cancer: a review of tumor initiation through tumor
metastasis. Prostaglandins, 21, 833-864.
KUNG, W., BECHTEL, E., SALOKANGAS, A., PREISZ, J., HUBER, P.,
TORHORST, T., JUNGMAN, A., KALMADGE, K. & EPPEN-
BERGER, U. (1977). Altered levels of cyclic nucleotides, cyclic
AMP phosphodiesterase and adenyl cyclase activities in normal,
dysplastic and neoplastic human mammary tissue. FEBS Lett.,
82, 102-106.
LANG, E.K. & DEKERNION, J.B. (1981). Transcatheter embolization
of advanced renal cell carcinoma with radioactive seeds. J. Urol.,
126, 581-586.
LYNCH, N.R., CASTES, M., ASTOIN, M. & SALOMON, J.C. (1978).
Mechanism of inhibition of tumor by aspirin and indomethacin.
Br. J. Cancer, 38, 503-512.
MALACHI, T., CHAIMOFF, Ch., FELLER, N. & HALBRECHT, I.
(1981). Prostaglandin E2 and cyclic AMP in tumor and plasma of
breast cancer patients. J. Cancer Res. Clin. Oncol., 102, 71-79.
MILAS, L., FURUTA, Y., HUNTER, N., NISHIGUCHI, I. & RUNKEL, S.
(1990). Dependence of indomethacin-induced potentiation of
murine tumor radioresponse on tumor host immunocompetence.
Cancer Res., 50, 4473-4477.
MINTON, J.P., MATTEWS, R.H. & WEISENBAUGH, T.W. (1976).
Elevated adenosine 3'5'-cyclic monophosphate levels in human
and animal tumors in vivo. J. Natl Cancer Inst., 57, 39-41.
PORTEDER, H., MATEJKA, M., ULRICH, W. & SINZINGER, H. (1984).
The cyclooxygenase and lipoxygenase pathways in human oral
cancer tissue. J. Max. Fac. Surg., 12, 145-147.
POWLES, T.J., ALEXANDER, P. & MILLER, J.L. (1978). Enhancement
of anticancer activity of cytotoxic chemotherapy with protection
of normal tissues by inhibition of PG synthesis. Biochem. Phar-
macol., 27, 1389-1392.
ROBERTSON, R.P., BAYLINK, D.J., MARINI, J.J. & ADKISON, H.W.
(1975). Elevated prostaglandins and suppressed parathyroid hor-
mone associated with hypercalcemia and renal cell carcinoma. J.
Clin. Endocrinol. Metab., 41, 164-167.
ROBERTSON, R.P., WESTCOTT, K.R., STORM, D.R. & RICE, M.G.
(1980). Down-regulation in vivo of PGE receptors and adenylate
cyclase stimulation. Am. J. Physiol., 239, E75-E80.
SCATCHARD, G. (1949). The attractions of proteins for small
molecules and ions. Ann. N.Y. Acad. Sci., 51, 660-672.
SHEPPARD, J.R. (1972). Difference in the cyclic adenosine 3'5'-
monophosphate levels in normal and transformed cells. Nature
New Biol., 236, 14-16.
SKUBALLA, W. & VORBRUGGEN, H. (1983). Synthesis of iloprost
(ZK36374): a chemically stable and biologically potent prostacyc-
lin analog. Adv. Prostagi. Thrombox. Leukotr. Res., 11, 299-305.
STEVENS, R.H., LOVEN, D.P., OSBORNE, J.W. & PRALL, J.L. (1978).
Cyclic nucleotide concentrations and X-ray induced rat small
intestinal cancer. Cancer Lett., 4, 325-332.
VIRGOLINI, I., HERMAN, M. & SINZINGER, H. (1988). Decrease of
prostaglandin I2 binding sites in thyroid cancer. Br. J. Cancer, 58,
584-588.
VIRGOLINI, I., SINZINGER, H., MULLER, Ch. & HERMAN, M. (1989).
Human hepatocellular cancers show a decreased prostaglandin El
binding capacity. Br. J. Cancer, 59, 407-409.
VIRGOLINI, I., LI, S.R., SILLABER, Ch., MAJDIC, O., SINZINGER, H.,
LECHNER, K., BETTELHEIM, P. & VALENT, P. (1992). Charac-
terization of prostaglandin (PG) binding sites expressed on
human basophils. Evidence for a PGE,, PGI2 and a PGD2-
receptor. J. Biol. Chem., 267, 12700-12708.
WALDEN, T.L., PATCHEN, J.M. & SNYDER, S.L. (1987). 16,16-
Dimethyl prostaglandin E2 increases survival in mice following
irradiation. Radiat. Res., 109, 440-448.
WANDL, E.O., ONO, K., KAIN, R., HERBSTHOFER, T., HIENERT, G.
& HORBARTH, K. (1989). Linear correlation between surviving
fraction and the micronuclear frequency. Int. J. Radiat. Biol., 56,
771 -775.
ZIBOH, V.A., MILLER, A.M., YUNIS, A. & JIMENEZ, J. (1981).
Arachidonic acid metabolism by rat chloroleukemia cells in cul-
ture. Cancer Res., 41, 12-17.